These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38809367)

  • 1. Implementation of Guideline-Based HBV Reactivation Management in Patients with Chronic HBV Infections of HBsAg or Resolved HBV Infection Undergoing Immunosuppressive Therapy.
    Tanaka Y; Nakamoto D; Piao Y; Mizutani H; Wakabayashi R; Saito Y; Kwon KM; Dickinson H
    Infect Dis Ther; 2024 Jul; 13(7):1607-1620. PubMed ID: 38809367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
    Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
    PeerJ; 2019; 7():e7481. PubMed ID: 31565551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overuse of prophylaxis in HBsAg and/or anti-HBc positive patients after increasing awareness to prevent reactivation in patients receiving immunosuppressive therapies: How rational are our prophylaxis decisions according to the literature?
    Yenilmez E; Cetinkaya RA
    Infez Med; 2019 Sep; 27(3):299-307. PubMed ID: 31545774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
    Yeh ML; Huang CF; Huang CI; Holmes JA; Hsieh MH; Tsai YS; Liang PC; Tsai PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Chung RT; Yu ML
    J Hepatol; 2020 Jul; 73(1):62-71. PubMed ID: 32061869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Su YC; Lin PC; Yu HC; Wu CC
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study.
    Onozawa M; Kusumoto S; Najima Y; Hashimoto H; Okada K; Tamaki M; Tanaka M; Sato T; Takahashi T; Hatano K; Onodera K; Moriuchi Y; Yakushijin K; Kanda J; Nagafuji K; Ogata M; Nakano N; Tamori A; Mizokami M
    Transplant Cell Ther; 2024 Mar; 30(3):330.e1-330.e8. PubMed ID: 38242442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
    Ito S
    Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J; Li W; Peng X; Tan Z; Tan M; Zhang C; Wang W; Xu Z; Zhou G
    Int Urol Nephrol; 2017 Mar; 49(3):475-482. PubMed ID: 28032257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014.
    Patel A; Yapali S; Lok AS
    Hepatol Int; 2016 Jan; 10(1):139-46. PubMed ID: 26272106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation.
    Tamori A; Kimura K; Kioka K; Enomoto H; Odagiri N; Kozuka R; Uchida-Kobayashi S; Enomoto M; Kawada N; Mizokami M
    J Med Virol; 2021 Jun; 93(6):3679-3687. PubMed ID: 32940921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
    Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
    Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
    Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
    Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment.
    Lee PH; Huang YH; Hsu YW; Chen KC; Hsu KH; Lin H; Lee TY; Tseng JS; Chang GC; Yang TY
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36615034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
    Sato K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy.
    Oketani M; Ido A; Uto H; Tsubouchi H
    Hepatol Res; 2012 Jul; 42(7):627-36. PubMed ID: 22686858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.